Latest News
Search News
Pancreatic Cancer UK Grand Challenge
27th July 2018
Our Director, Prof Nicholas Lemoine, and a team of researchers from the BCI and King’s College London have been awarded the Pancreatic Cancer UK (PCUK) Grand Challenge- PCUK’s largest ever research fund. The grant will be […]
Read more
CRUK Gibraltar Committee visit the BCI
18th July 2018
We were recently visited by two members of the CRUK Gibraltar Committee, Giovi and Deborah, who came to the BCI for a laboratory tour with Dr Ana Rio-Machin, a postdoctoral researcher in the Centre for Haemato-Oncology. Ana’s research focuses on leukaemia, a type of blood cancer in which patients present an abnormal growth of white blood cells.
Read more
Uncovering the evolutionary history of IBD-associated colorectal cancer
11th July 2018
A team of researchers from the BCI, led by Prof Trevor Graham, Lead of the Evolution and Cancer Biology Laboratory, have reported the genetic events involved in the early development of bowel cancer in patients with inflammatory bowel disease (IBD). Such knowledge may be able to be exploited to design simple diagnostic tests to stratify patients with IBD at high risk of developing cancer.
Read more
Prof Trevor Graham part of ‘ACE’ research centre within NCI’s Cancer Systems Biology Consortium
19th June 2018
BCI’s Prof Trevor Graham, Lead of the Evolution and Cancer Biology Laboratory, is part of Arizona State University (ASU)’s recently funded research centre called ‘ACE’ (the Arizona Cancer Evolution Centre), which has been awarded more than $8.5 million over five years to serve as one of 13 research hubs within the National Cancer Institute (NCI)’s Cancer Systems Biology Consortium (CSBC).
Read more
BCI at the 2018 ASCO Annual Meeting: Results from the PAKT and ABACUS trials
15th June 2018
Professors Peter Schmid and Thomas Powles attended this year’s ASCO Annual Meeting, which took place from 1st-5th June in Chicago. Prof Schmid, presented data from the PAKT trial- a trial investigating the addition of a novel drug called AZD5363 to a standard chemotherapy regimen as a treatment for triple-negative breast cancer (TNBC). Prof Powles presented results from the ABACUS trial, which is investigating the efficacy and safety of a drug called atezolizumab administered prior to cystectomy in muscle invasive bladder cancer. The ABACUS trial was selected as one of the highlights of this year’s meeting.
Read more
Research explainer: Mis-segregation of human chromosomes
13th June 2018
Dr Sarah McClelland from Barts Cancer Institute, Queen Mary University of London, has recently published new research in the journal Cell Reports revealing new insights into why cell division can sometimes go wrong.
Read more